Thomas Bardin

Summary

Country: France

Publications

  1. Bardin T, Chalès G, Pascart T, Flipo R, Korng Ea H, Roujeau J, et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83:314-7 pubmed publisher
    ..80-18.74]). The risk of skin reaction with febuxostat seems moderately increased in patients with a history of cutaneous adverse events with allopurinol. This moderate increase does not support the cross-reactivity of the two drugs. ..
  2. Bardin T, van de Laar M. The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis. Joint Bone Spine. 2015;82 Suppl 1:eS30-2 pubmed publisher
    ..When deciding as to whether a patient with gouty arthritis is an appropriate candidate for canakinumab treatment, several key clinical considerations should be kept in mind, which are discussed herein. ..
  3. Bardin T. Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence. Joint Bone Spine. 2015;82 Suppl 1:eS9-16 pubmed publisher
  4. Bardin T, Richette P. [The epidemiology and genetic of gout]. Presse Med. 2011;40:830-5 pubmed publisher
    ..Gout and hyperuricaemia are associated with hypertension, diabetes mellitus, metabolic syndrome, and renal and cardiovascular diseases. Genetic studies have found that variants of GLUT9 and ABCG2 were associated with urate levels...
  5. Ottaviani S, Moltó A, Ea H, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15:R123 pubmed
    ..Its long-term use could be limited by infectious complications. ..